Oxford Health NHS
NHS Foundation Trust

NHS
Oxfordshire
Clinical Commissioning Group

GLP-1 Receptor Agonist Treatment Agreement Form and Checklist

To be used alongside GLP-1 Receptor Agonist Guidelines

Date seen:	**DSN name:**
Name: **NHS number:** **DOB:** **Tel number:**	**GP name:** **GP Practice:**

Exclusion criteria:	**Yes**	**No**
eGFR (within last 2 mths)_____ ▪ Dulaglutide < 15 AVOID ▪ Liraglutide < 15 AVOID ▪ Semaglutide <15 AVOID	☐	☐
Triglycerides in last 2 mths _____mmol/l **(CONSIDER RISK IF ABOVE 5MMOL/L)**	☐	☐
Alcohol intake_____units/wk **(If above national recommendations discuss increased pancreatitis risk)**	☐	☐
Biliary or pancreatic surgery within last 6 mths	☐	☐
History of pancreatitis	☐	☐
Heart Failure NYHA class IV	☐	☐
Inflammatory bowel disease	☐	☐
Diabetic gastroparesis	☐	☐
Planned pregnancy, inadequate contraception or breastfeeding	☐	☐
CAUTION IN: Retinopathy grade R2/R3/M1/P1 (semaglutide only)	☐	☐
HbA1c greater or equal to 75 mmol/mol (9%) (semaglutide only)	☐	☐

Warnings:	**Yes**	**No**
Person willing to inject?	☐	☐
Person warned of possible side effects?	☐	☐
Person warned of risk of renal impairment?	☐	☐
Person warned of risk of pancreatitis?	☐	☐
Instructions given to seek prompt advice if experiencing persistent severe abdominal pain with or without vomiting?	☐	☐

GLP-1 chosen:

- Semaglutide ☐
- Dulaglutide ☐
- Liraglutide ☐
- Other (state why) ☐
- None ☐

Advised re NICE 6 month review criteria:	☐	☐
To take away: Written information	☐	☐
DVLA information:	☐	☐

Liraglutide/Semaglutide/Dulaglutide has been prescribed for you to help reduce your blood glucose levels and help you to lose weight.

Liraglutide/Semagluitde/Dulaglutide is not beneficial in everyone and the National Institute for Health and Care Excellence (NICE) have advised that treatment should only be continued for people who have a reasonable benefit; defined by NICE as a reduction in HbA1c (long term glucose reading) of 1% point (DCCT units) or 11mmol/mol (IFCC units) or more and a reduction in weight of 3% or more after 6 months of treatment.

Over the next 6 months we will monitor your HbA1c and weight to assess if you are one of the people who benefit from the treatment. Liraglutide/Semaglutide/Dulaglutide will only usually be continued beyond 6 months in people who have a reasonable benefit from the treatment as stated above.

In occasional cases, where there has been a very good reduction in either HbA1c or weight (above that suggested by NICE) but not in both, we may still decide that it is beneficial to continue using Liraglutide/Semaglutide/Dulaglutide.

Prior to commencing therapy:		**At 3 months:**		**At 6 months:**		
Date:		**Date:**		**Date:**		
HbA1c						
Wt (kg)						
BMI (kg/m2)						
eGFR (ml/min/1.73m2)						
%age weight loss 3 & 6 months				Target weight loss of at least 3% achieved?	YES	NO
HbA1c reduction 3 & 6 months				Target HbA1c reduction of at least 11mmol/mol (IFCC units) or 1% point (DCCT units) achieved?	YES	NO

Agreement

The information above has been explained to me and I understand that treatment with Liraglutide/Semaglutide/Dulaglutide should be discontinued after 6 months if the medicine does not appear to be having a reasonable benefit.

Name …….

Signature ……